LIMN
Liminatus Pharma, Inc.Company with tickers: LIMN, LIMNW
CIK
1971387
CUSIP
53271X108
Shares Outstanding
44,877,633
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $1,100,898 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | $400,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-1,100,898 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-1,123,714 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.03 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.03 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |